115 related articles for article (PubMed ID: 1482709)
1. A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.
Hum Gene Ther; 1992 Dec; 3(6):691-703. PubMed ID: 1482709
[No Abstract] [Full Text] [Related]
2. A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma.
Hum Gene Ther; 1992 Dec; 3(6):677-90. PubMed ID: 1482708
[No Abstract] [Full Text] [Related]
3. Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma.
Hum Gene Ther; 1992 Dec; 3(6):665-76. PubMed ID: 1482707
[No Abstract] [Full Text] [Related]
4. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
Marumo K; Tazaki H
Prog Clin Biol Res; 1990; 350():263-73. PubMed ID: 2117286
[No Abstract] [Full Text] [Related]
5. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma.
Schmidt-Wolf IG; Huhn D; Neubauer A; Wittig B
Hum Gene Ther; 1994 Sep; 5(9):1161-8. PubMed ID: 7530496
[No Abstract] [Full Text] [Related]
7. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
Kroeze SG; Daenen LG; Nijkamp MW; Roodhart JM; de Gast GC; Bosch JL; Jans JJ
J Urol; 2012 Aug; 188(2):607-14. PubMed ID: 22704448
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cellular therapy of renal carcinoma.
West WH
Prog Clin Biol Res; 1989; 303():689-96. PubMed ID: 2789392
[No Abstract] [Full Text] [Related]
10. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
Holdener EE; Emmons RP; Brunda M; Evans L; Levitt D
Prog Clin Biol Res; 1990; 348():61-9. PubMed ID: 2201034
[No Abstract] [Full Text] [Related]
11. [Immunotherapy of metastatic renal cell cancer].
Manseck A; Wirth M
Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
[TBL] [Abstract][Full Text] [Related]
12. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
Franzke A; Buer J; Probst-Kepper M; Lindig C; Framzle M; Schrader AJ; Ganser A; Atzpodien J
Cancer Biother Radiopharm; 2001 Oct; 16(5):401-9. PubMed ID: 11776757
[TBL] [Abstract][Full Text] [Related]
13. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
[TBL] [Abstract][Full Text] [Related]
14. [Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization].
Pomer S; Thiele R; Staehler G; Drehmer I; Löhrke H; Schirrmacher V
Urologe A; 1995 May; 34(3):215-20. PubMed ID: 7610516
[TBL] [Abstract][Full Text] [Related]
15. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
[TBL] [Abstract][Full Text] [Related]
17. Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma.
Osanto S; Brouwenstÿn N; Vaessen N; Figdor CG; Melief CJ; Schrier PI
Hum Gene Ther; 1993 Jun; 4(3):323-30. PubMed ID: 8338879
[TBL] [Abstract][Full Text] [Related]
18. [Anatomopathological findings correlated with high-dose recombinant interleukin-2. Review of the literature and description of 2 autopsy cases].
Canzonieri V; Monfardini S; Carbone A
Pathologica; 1992; 84(1092):473-81. PubMed ID: 1491889
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma.
Cao S; Wang YL; Ren XB; Yu JP; Ren BZ; Zhang XW; Zhang WH; Han Y
Cancer Biother Radiopharm; 2011 Aug; 26(4):503-10. PubMed ID: 21812652
[TBL] [Abstract][Full Text] [Related]
20. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.
Kugler A; Stuhler G; Walden P; Zöller G; Zobywalski A; Brossart P; Trefzer U; Ullrich S; Müller CA; Becker V; Gross AJ; Hemmerlein B; Kanz L; Müller GA; Ringert RH
Nat Med; 2000 Mar; 6(3):332-6. PubMed ID: 10700237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
